upgraded

The OECD has significantly updated its UK growth forecasts, giving credit to Rachel Reeves' £70bn-a-year public spending package. The UK economy is now expected to grow by 0.9% in 2024 and 1.7% in 2025, up from May forecasts of…

At Lightspark Sync, Lightspark's first partner summit on Thursday, the company announced new products and features that will allow users to make global payments using both bitcoin and fiat currencies.The company announced that it has…

Goldman Sachs raised its call on Chinese stocks to overweight, due to optimism over Beijing's stimulus measures.Bloomberg (portal) with the report. In short (very):Chinese stocks could rise another 15% to 20% if the authorities fulfill…

Investing.com - Analysts at TD Cowen raised their rating on CVS Health (NYSE:) to "buy" from "hold," citing changes to Medicare Advantage plan benefits for 2025 announced earlier this week. Along with peers like Humana (NYSE:) and Cigna…

On Tuesday, Jefferies upgraded Clorox (NYSE:) stock to buy from hold, setting a new price target of $187, up from the previous price of $174. The company highlighted the positive outlook for the company's future performance, anticipating a…

Banks and microfinance banks have begun testing the updated system for sending high-value financial transactions to speed up transfers while tightening screening for fraud. Banks on Monday began testing the updated system that…

Investing.com - Here's a professional summary of what Wall Street analysts said over the past week. InvestingPro subscribers always get priority access to market-moving AI analyst commentary. Upgrade today! Petrobras What happened? Morgan…

bodnarchuk/iStock via Getty Images Newmont (NYSE: No) was upgraded to sector outperform from sector perform with a $59 price target, but AngloGold Ashanti (AU) was downgraded to sector underperform from sector perform with a $30 price…

Benchmark raised its rating on Booking Holdings (NASDAQ:) from Hold to Buy, and set a new price target of $4,700 per share. Despite current economic concerns and elevated investor expectations, Benchmark analysts believe the company's…

On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered…